Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

AstraZeneca’s Head Of R&D Asia Patrick Keohane On Balancing East And West: An Interview With PharmAsia News (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

AstraZeneca's Head of R&D in Asia Patrick Keohane sat down with PharmAsia News' Australia bureau to talk about AstraZeneca's footprint in Asia and how the company's thinking is changing as a result of looking toward Asia.

You may also be interested in...



Generics History Hobbles Trial Work In China

NEW YORK - Fast, unpredictable change in fragmented China - where companies face retention and regulatory challenges despite in many cases being revenue-generating - brings risk as well as possibility

Generics History Hobbles Trial Work In China

NEW YORK - Fast, unpredictable change in fragmented China - where companies face retention and regulatory challenges despite in many cases being revenue-generating - brings risk as well as possibility

AstraZeneca’s Head Of R&D Asia Patrick Keohane On Balancing East And West: An Interview With PharmAsia News (Part 2 of 2)

AstraZeneca's Head of R&D in Asia Patrick Keohane sat down recently with PharmAsia News' Australia bureau to talk about AstraZeneca's footprint in Asia and how the company's thinking is changing as a result of looking toward Asia.

Table

View full table

Tags:
Latest Headlines

Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval

Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

Sanofi Skates To Where The Puck Is With Immunology

See All
UsernamePublicRestriction

Register

SC069003

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By